Information about whether Anagrelide has been included in medical insurance

Anagrelide (Anagrelide), as a prescription drug specifically used to lower platelets, is mainly used in the management of thrombocytosis secondary to myeloproliferative neoplasms. Since this type of disease requires long-term treatment, whether the drug is covered by medical insurance and whether the price is affordable has always been one of the issues that patients are most concerned about. At present, a domestic version of anagrelide is available in China, but it is not included in the national medical insurance directory, so the overall cost still poses a certain burden to some patients.

According to information, the market price of domestically produced anagrelide is generally around 7,000 yuan, but there may be certain differences in hospitals in different regions and different batches of purchases, so the final price still needs to be determined by the local hospital pharmacy. Since they are not covered by medical insurance, patients need to bear the cost of drugs themselves when purchasing them. This is one of the important reasons why many patients pay attention to treatment expenses and seek long-term medication plans.

The reason why anagrelide is not included in medical insurance is related to the particularity of its applicable diseases, market size, clinical use scope and the update cycle of the medical insurance catalog. Adjustments to the medical insurance catalog usually require comprehensive factors such as drug efficacy, safety, cost-effectiveness, and the size of the population covered. Therefore, not all marketed drugs can be immediately included in the medical insurance. In the experience of some countries, similar specialty drugs usually undergo a long observation period. Whether they will be included in domestic medical insurance in the future still requires continued attention to policy updates.

Although not included in Medicare, anagrelide's clinical importance is increasing. It features clear targets and intervention at the megakaryocyte stage, and can effectively reduce the risk of thrombosis caused by excessive platelet proliferation. It is one of the cytoreductive treatment options recommended by international guidelines. For patients who really need long-term treatment, it has clear significance in stabilizing platelet counts and improving symptoms.

References: https://go.drugbank.com/drugs/DB00261